|
|
작성일 : 15-02-06 13:03
|
iCAD ANNOUNCES MORE THAN 1,000 EARLY STAGE BREAST CANCER PATIENTS TREATED WITH INTRAOPERATIVE RADIATION THERAPY (IORT) USING THE XOFT SYSTEM
|
|
|
글쓴이 :
최고관리자
 조회 : 4,606
|
 http://www.xoftinc.com/documents/Xoft1000IORTpatientsFINAL.pdf [1672] |
NASHUA, N.H. and Miami– March 6, 2014 – iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced image analysis and radiation therapy solutions for the early identification and treatment of cancer, today announced at the 31st Annual Miami Breast Cancer Conference that more than 1,000 early stage breast cancer patients have been treated with Intraoperative Radiation Therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy System®. With IORT, a full course of radiation therapy is delivered to the patient in the operating room immediately following lumpectomy, replacing six to eight weeks of daily traditional radiation.
“The growing adoption and utilization of the Xoft System further validates that IORT is an attractive alternative for the treatment of early stage breast cancer because of its compelling benefits to patients,” said Ken Ferry, President and CEO of iCAD. “By offering IORT with the Xoft System, hospitals are able to expand their comprehensive breast care programs by providing appropriate patients with the option to complete a full dose of radiation therapy in a single treatment.”
“The Xoft System provides patients with a treatment option that helps mitigate the logistical burdens often associated with a traditional course of radiation treatment,” said Barbara Schwartzberg, M.D., Director of Breast Services, Sarah Cannon/HealthONE, Rose Medical Center. “IORT with the Xoft System delivers radiation directly into the tumor cavity while the patient is still under anesthesia, minimizing radiation exposure to surrounding healthy tissue. Because the treatment is delivered in one dose, my patients are able to maintain their quality of life and return to their jobs and families quickly.”
A post-market, prospective, multi-center, clinical trial evaluating the safety, efficacy and cosmetic outcomes associated with IORT for early-stage breast cancer with the Xoft System is currently underway at hospitals across the U.S.
iCAD to Host Lunch Symposium during Miami Breast Cancer Conference
On March 8, 2014, iCAD will host the Breast IORT Symposium: Clinical and Practice Perspectives from 1:00 p.m. EST – 2:15 p.m. EST at the Fontainebleau Miami Beach Hotel during the 31st Annual Miami Breast Cancer Conference taking place March 6 – March 9, 2014. Leading breast cancer surgeons will present and discuss their IORT clinical experience, which includes more than 400 patients. Topics will include IORT techniques, clinical advancements, scientific evidence, case review and IORT study protocol. The event is open to all conference attendees and the
public. For more details or to register, please visit: http://www.xoftinc.com/IORTsymposiumreg.html
iCAD will also showcase the Xoft System during the Miami Breast Cancer Conference at Booth #22.
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com
|
|
|
HOME > NEWS
